Our Development Programs


Medicines Development for Global Health (MDGH) successfully registered moxidectin with the US Food and Drug Administration in 2018. Moxidectin is the first new drug for the treatment of river blindness in 20 years. Funded by a US $13 million investment from the Global Health Investment Fund, MDGH re-established quality manufacturing and testing of moxidectin, the clinical pharmacology program, development of additional non-clinical data, completion of the Phase III clinical trial, a pharmacokinetic and QT clinical study, and the compilation of the New Drug Application for the US FDA.

MDGH is committed to delivering moxidectin for the treatment of onchocerciasis on a cost-recovery basis and, with the Global Health Investment Fund, to continue to research other potential human uses of moxidectin.

There's a story behind the 'AKKA' embossed on our moxidectin tablets

Our Current Roster of Global Health Projects, Across Stages of Development

Medicines Development's Product Pipeline Medicines Development's Product Pipeline

To learn more about moxidectin in clinical trials,

Our next program will focus on the treatment and prevention of scabies, which affects up to 200 million people worldwide.

“Our goal is to impact as many lives as possible by eliminating as many neglected diseases as possible.”

— Mark Sullivan, Founder and Managing Director


Moxidectin is an FDA-approved (NDA 210867) medication for the treatment of onchocerciasis due to Onchocerca volvulus in patients aged 12 years and older. Moxidectin is considered an investigational agent as a repeat dose treatment for onchocerciasis in patients with onchocerciasis less than 12 years of age and in patients with clinical conditions other than onchocerciasis (eg, scabies).

What is River Blindness

Large (4 MB) versions of the above infographic are available here:
Medical/Scientific Language: Horizontal | Vertical
Simplified Language: Horizontal | Vertical


Scabies is a skin infection that is caused by a microscopic mite (Sarcoptes scabiei var. hominis) that is transmitted primarily through person-to-person contact. Infection can result in debilitating itchiness with associated sleep disturbance and reduced ability to concentrate. More seriously, infection is a risk factor for the development of infected skin sores, which can cause long-term complications such as rheumatic heart disease or post-streptococcal glomerulonephritis. Scabies is estimated to affect more than 200 million people worldwide at any time. The highest rates occur in resource-poor countries with hot, tropical climates, where infestation can be endemic, but outbreaks can occur anywhere. While there are effective treatments for scabies, moxidectin is being developed as a single-dose oral medicine to treat and prevent scabies infection.

If you share our passion for neglected diseases and have a development program that needs expert support, let’s connect.

Sign up for our newsletter to stay current on
the work MDGH is doing in neglected diseases

Thank you for signing up.